A Systems Pharmacology Approach to Diabetes Management: Integrating Drug Therapy, Lifestyle Modulation, and Personalised Treatment Algorithm

Diabetes mellitus represents one of the most formidable chronic disease burdens of the twenty-first century. The International Diabetes Federation (IDF) Atlas (10th edition, 2021) documented 537 million adults living with diabetes globally, a figure expected to escalate to 783 million by 2045. In South and Southeast Asia alone, India hosts over 101 million individuals with diabetes  now surpassing China as the nation with the highest absolute disease burden [1]. The economic ramifications are equally staggering, with global diabetes-attributable expenditure estimated at USD 966 billion in 2021.

The pathophysiology of T2DM  once simplistically attributed to impaired insulin secretion and peripheral insulin resistance — has been dramatically reframed over the past two decades. Contemporary understanding embraces an "ominous octet" of pathophysiological mechanisms described by DeFronzo, encompassing hepatic glucose overproduction, reduced incretin effect, hyperglucagonaemia, enhanced renal glucose reabsorption, neurotransmitter dysfunction, accelerated lipolysis, and beta-cell failure superimposed on muscle insulin resistance [2]. This mechanistic complexity renders single-target pharmacotherapy fundamentally insufficient for achieving durable glycaemic control and  more critically  for preventing the cardiovascular, renal, and neurological complications that drive morbidity and premature mortality in this population [3].

Systems pharmacology  the quantitative study of drug action across biological networks, from molecular targets to organ-level and whole-body pharmacodynamic effects  provides an epistemological framework ideally suited to diabetes therapeutics [4]. By integrating molecular target biology, polypharmacology, drug-drug interactions, and patient-level physiological parameters into computational and clinical decision models, systems pharmacology enables the rational design of combination regimens that exploit synergistic pathway redundancy while minimising off-target harm [5].

Simultaneously, the primacy of lifestyle intervention in diabetes prevention and management has been unequivocally established. The landmark Diabetes Prevention Program (DPP) demonstrated that intensive lifestyle modification (7% weight reduction and ≥150 minutes/week physical activity) reduced T2DM incidence by 58% in high-risk individuals  significantly outperforming metformin monotherapy (31% reduction) [6]. Despite this evidence, lifestyle interventions remain inadequately integrated into pharmacotherapy algorithms in clinical practice, reflecting a compartmentalisation that systems pharmacology can structurally overcome.

This paper presents a comprehensive, evidence-grounded systems pharmacology framework for diabetes management. We review the mechanistic pharmacology of all major antidiabetic drug classes through the lens of network biology, examine the molecular mechanisms underlying lifestyle-induced metabolic modulation, and synthesise these streams into a personalised treatment algorithm that accommodates cardiorenal comorbidities, phenotypic heterogeneity, and patient-centred goals. Our framework incorporates recent cardiovascular outcome trial (CVOT) data, precision medicine genomics, digital health technologies, and behavioural pharmacology to offer a transformative approach to individualised diabetes care.

EPIDEMIOLOGY AND SYSTEMS-LEVEL PATHOPHYSIOLOGY

Global Burden and Phenotypic Heterogeneity

The epidemiological landscape of diabetes encompasses multiple clinical phenotypes with distinct pathophysiological underpinnings. While T2DM constitutes 90–95% of all diabetes cases, it exhibits substantial heterogeneity  a fact crystallised by Ahlqvist et al.'s landmark cluster analysis (2018), which identified five distinct T2DM subtypes in 8,980 newly diagnosed patients using hierarchical clustering of six variables: GADA positivity, age at diagnosis, BMI, HbA1c, beta-cell function (HOMA-B), and insulin resistance (HOMA-IR) [7]. These clusters demonstrated markedly different complications profiles and pharmacological responses, presaging the era of precision diabetes medicine.

Type 1 diabetes mellitus (T1DM), characterised by autoimmune beta-cell destruction and absolute insulin dependence, affects approximately 8.4 million globally, with incidence rising 3–4% annually in high-income countries. Latent autoimmune diabetes in adults (LADA)  the most common misdiagnosed form shares autoimmune aetiology with T1DM but progresses more slowly, often initially managed as T2DM until insulin dependence manifests [8]. Maturity-onset diabetes of the young (MODY), encompassing at least 14 monogenic subtypes, affects 1–5% of all diabetes patients and may require entirely different pharmacological approaches MODY2 (GCK mutations) rarely requires treatment, while MODY3 (HNF1A) is exquisitely sensitive to sulfonylureas [9].

Gestational diabetes mellitus (GDM) affects 14% of pregnancies globally, with profound implications for both maternal long-term T2DM risk (50% within 10 years) and offspring metabolic programming. The recognition of intra-individual glycaemic variability and continuous glucose monitoring (CGM)-derived metrics such as time-in-range (TIR) has further enriched the epidemiological characterisation of diabetes across its phenotypic spectrum [10].

Molecular Networks in T2DM Pathogenesis

From a systems biology perspective, T2DM pathogenesis can be modelled as a failure of homeostatic network resilience across interconnected physiological modules [11]. The insulin signalling cascade anchored by the insulin receptor substrate (IRS)-PI3K-AKT axis  interfaces with nutrient sensing pathways (mTORC1, AMPK), lipid metabolism networks (peroxisome proliferator-activated receptors), and inflammatory signalling (IKKβ-NF-κB, JNK) in ways that create self-reinforcing pathological loops. Lipid overload in hepatocytes activates diacylglycerol-PKCε signalling, impairing insulin receptor kinase activity and driving hepatic insulin resistance. Simultaneously, ceramide accumulation in skeletal muscle activates PP2A, dephosphorylating and inactivating AKT, while promoting inflammatory cytokine production [12].

The gut-brain axis emerges as a critical regulatory nexus in glucose homeostasis and T2DM pathophysiology. Gut-derived GLP-1, secreted from L-cells in response to nutrient ingestion, activates central and peripheral GLP-1 receptors to suppress appetite, slow gastric emptying, stimulate glucose-dependent insulin secretion, and inhibit glucagon release [13]. Gut microbiota dysbiosis  characterised by reduced Akkermansia muciniphila, Faecalibacterium prausnitzii, and Lactobacillus species alongside expansion of Bacteroides and Ruminococcus promotes increased intestinal permeability, lipopolysaccharide translocation, and systemic low-grade inflammation that exacerbates insulin resistance [14]. Short-chain fatty acids (SCFAs)  particularly butyrate and propionate  produced by gut microbial fermentation of dietary fibre activate free fatty acid receptor 2/3 (FFAR2/3) on L-cells and immune cells, modulating both GLP-1 secretion and inflammatory tone [15].

Adipose tissue dysfunction represents a pivotal node in the T2DM network. Visceral adipose tissue expansion activates macrophage polarisation toward pro-inflammatory M1 phenotype, promoting TNF-α, IL-6, and IL-1β secretion that directly impairs insulin signalling in hepatocytes and myocytes through serine phosphorylation of IRS-1/2 [16]. Adiponectin an insulin-sensitising adipokine secreted exclusively by adipocytes  is paradoxically reduced in obesity and T2DM, further impairing hepatic fatty acid oxidation and skeletal muscle glucose uptake via AMPK-dependent mechanisms.

Cardiorenal-Metabolic Syndrome Nexus

The concept of cardiorenal-metabolic (CRM) syndrome recognises the bidirectional, mechanistically linked dysfunction of the cardiovascular system, kidneys, and metabolic organs in T2DM [17]. Hyperglycaemia drives endothelial dysfunction through advanced glycation end-product (AGE) accumulation, polyol pathway activation, PKC-mediated NADPH oxidase upregulation, and impaired nitric oxide bioavailability. These mechanisms converge on accelerated atherosclerosis, left ventricular hypertrophy, and glomerular hyperfiltration establishing a self-perpetuating vascular injury cycle that fundamentally shapes both prognosis and pharmacological target selection [18].

The renin-angiotensin-aldosterone system (RAAS) occupies a central pathophysiological position in CRM syndrome. Hyperactivation of intrarenal RAAS promotes glomerular hypertension, mesangial expansion, and tubular fibrosis, while aldosterone excess drives myocardial fibrosis and sodium retention. ACE inhibitors and ARBs  while not primarily antidiabetic  form an essential pharmacological layer in diabetic nephropathy management by reducing intraglomerular pressure and albuminuria progression [19]. The recent emergence of finerenone (a non-steroidal mineralocorticoid receptor antagonist) as an agent demonstrably reducing CKD progression and cardiovascular events in diabetic kidney disease (FIDELIO-DKD and FIGARO-DKD trials) exemplifies the systems-level thinking that recognises shared pathophysiological nodes across end-organ compartments [20].

SYSTEMS PHARMACOLOGY OF ANTIDIABETIC AGENTS

Metformin: The Foundational Agent

Metformin (1,1-dimethylbiguanide) has occupied the position of first-line pharmacotherapy in T2DM for over six decades, a tenure unprecedented in metabolic medicine and reflecting its favourable benefit-risk profile, low cost, and pleiotropic mechanisms [21]. The primary mechanism  inhibition of mitochondrial complex I (NADH:ubiquinone oxidoreductase) reduces ATP production and triggers AMPK activation, which in turn suppresses hepatic gluconeogenesis by phosphorylating and inactivating CREB-regulated transcription coactivator 2 (CRTC2) [22]. AMPK activation additionally promotes skeletal muscle GLUT4 translocation, enhancing peripheral glucose uptake independently of insulin signalling.

Recent mechanistic investigations have elucidated additional metformin targets of pharmacological significance. Metformin activates lysosomal AMPK through a mechanism dependent on aldolase inhibition and v-ATPase, independent of mitochondrial effects [23]. In the gut, metformin inhibits sodium-glucose transporter 1 (SGLT1) in the intestinal brush border, reducing post-prandial glucose absorption, and modulates the gut microbiome  increasing Akkermansia muciniphila abundance and SCFA production  effects that may explain the dissociation between portal metformin concentrations and systemic AMPK activation [24].

The cardiovascular benefits of metformin extend beyond glycaemic control. The UKPDS 34 substudy demonstrated 39% reduction in myocardial infarction and 36% reduction in all-cause mortality in overweight T2DM patients on metformin monotherapy, effects exceeding those explained by HbA1c reduction alone [25]. Proposed mechanisms include endothelial protection via eNOS phosphorylation, anti-platelet effects, reduction of vascular smooth muscle proliferation, and direct AMPK-mediated cardioprotection against ischaemia-reperfusion injury.

GLP-1 Receptor Agonists: Incretin-Based Systems Modulation

GLP-1 receptor agonists (GLP-1RAs) represent the most significant pharmacological advance in T2DM management of the past decade, with their clinical utility extending far beyond incretin mimicry to encompass cardiovascular protection, renal benefit, and weight reduction of magnitude approaching bariatric surgery [26]. The GLP-1 receptor  a class B G-protein-coupled receptor coupled to Gs, triggering cAMP-PKA-CREB signalling  is expressed not only in pancreatic beta-cells but also in cardiac myocytes, vascular endothelium, renal tubular cells, hepatocytes, hypothalamic neurons, and vagal afferents, providing a mechanistic basis for the drug class's diverse systemic effects.

The cardiovascular outcome trials (CVOTs) conducted under FDA guidance have irrevocably established GLP-1RA superiority in high-risk T2DM populations. LEADER (liraglutide, n=9,340) demonstrated 13% reduction in three-point major adverse cardiovascular events (3P-MACE) and 22% reduction in cardiovascular mortality [27]. SUSTAIN-6 (semaglutide, n=3,297) showed 26% MACE reduction driven primarily by non-fatal stroke reduction [28]. REWIND (dulaglutide, n=9,901) demonstrated cardiovascular benefit in a broader, lower-risk population  12% MACE reduction extending the evidence base beyond secondary prevention [29].

At the molecular level, GLP-1RA cardiovascular protection involves multiple mechanisms: direct myocardial GLP-1R activation reducing ischaemia-reperfusion injury, anti-atherosclerotic effects through NF-κB suppression and macrophage foam cell regression, BP reduction via natriuresis and sympatholytic effects, and anti-arrhythmic action through cardiac GLP-1R-mediated ion channel modulation [30]. The hepatic GLP-1R (contentiously present at low expression) and indirect hepatic effects via vagal afferents may contribute to the NAFLD/NASH improvements observed with liraglutide (LEAN trial) and semaglutide (ESSENCE trial, Phase 3) [31].

Semaglutide has achieved further pharmacological milestone status with the approval of oral formulation (Rybelsus, 3–14 mg daily) using the SNAC absorption enhancer technology, and the weekly injectable 2.4 mg semaglutide (Wegovy) for obesity management — demonstrating 14.9% body weight reduction in the STEP-1 trialeffectively blurring the therapeutic distinction between antidiabetic and anti-obesity pharmacology [32].

Fig.1  DRUG THERAPY IN DIABETES

SGLT2 Inhibitors: Renal Glycosuria and Cardiorenal Protection

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an insulin-independent therapeutic modality that exploits the kidney's glucose reabsorption capacity as a glycaemic target. Under normoglycaemia, the kidney filters approximately 180g glucose daily, 90% reabsorbed by SGLT2 in the proximal convoluted tubule (S1/S2 segment) and the remainder by SGLT1 in the S3 segment [33]. In T2DM, adaptive SGLT2 upregulation enhances glucose reabsorption as a homeostatic response to hyperglycaemia, paradoxically sustaining elevated glucose levels. SGLT2 inhibition induces glycosuria of 60–90g/day, achieving HbA1c reductions of 0.6–1.0% while simultaneously promoting osmotic diuresis, natriuresis, and caloric deficit [34].

The cardiorenal protective effects of SGLT2 inhibitors  revealed through pivotal CVOTs  have transformed their pharmacological status from antidiabetic agents to organ-protective cardiovascular medicines [35]. EMPA-REG OUTCOME (empagliflozin, n=7,020) demonstrated 14% reduction in 3P-MACE, 38% reduction in cardiovascular mortality, and 35% reduction in hospitalisation for heart failure  findings of such clinical magnitude that they prompted urgent label revisions and guideline updates within months of publication [36]. CREDENCE (canagliflozin) and DAPA-CKD (dapagliflozin) subsequently demonstrated robust renoprotection  including among non-diabetic CKD patients in DAPA-CKD  establishing SGLT2i as disease-modifying agents in diabetic nephropathy [37].

The mechanistic underpinning of SGLT2i heart failure benefits extends beyond haemodynamic effects of diuresis. The "thrifty substrate hypothesis" proposes that SGLT2 inhibition promotes myocardial metabolic reprogramming from glucose to ketone bodies (β-hydroxybutyrate) a more oxygen-efficient fuel improving cardiac efficiency in the failing heart [38]. Epicardial adipose tissue reduction, sympathetic nervous system inhibition via renal afferent pathways, NLRP3 inflammasome suppression, and autophagy induction represent additional mechanistic contributions to the multifaceted cardiorenal protective phenotype of this drug class [39].

DPP-4 Inhibitors: Incretin Enhancement with Safety Considerations

Dipeptidyl peptidase-4 (DPP-4) inhibitors achieve their antidiabetic effects by preventing the enzymatic degradation of endogenous GLP-1 and GIP (glucose-dependent insulinotropic peptide), extending their half-lives from 1–2 minutes to 12–14 hours. DPP-4  a multifunctional serine exopeptidase expressed on T-lymphocytes (as CD26), epithelial cells, endothelium, and soluble in plasma  cleaves a diverse repertoire of substrates beyond incretins, including neuropeptide Y, B-type natriuretic peptide, stromal cell-derived factor-1 (SDF-1), and numerous immunomodulatory peptides [40].

The weight-neutral profile, low hypoglycaemia risk, and once-daily oral administration have established DPP-4 inhibitors as valuable agents in elderly populations and those with hypoglycaemia concerns. However, cardiovascular safety data have been nuanced: SAVOR-TIMI 53 (saxagliptin) demonstrated a significant 27% increase in hospitalisation for heart failure  attributed to saxagliptin's broader substrate specificity, including inhibition of SDF-1 degradation and consequent myocardial accumulation of SDF-1 promoting maladaptive cardiac remodelling [41]. TECOS (sitagliptin) and EXAMINE (alogliptin) found no cardiovascular benefit or harm, establishing non-inferiority rather than superiority.

Insulin Analogues: Physiological Replacement and Dose Optimisation

Insulin therapy remains the most potent and universally applicable pharmacological intervention across all stages and phenotypes of diabetes. The pharmacological evolution from animal-derived insulins to recombinant human insulin, and subsequently to analogue insulins with engineered pharmacokinetic profiles, represents one of the most consequential trajectories in pharmaceutical science [42]. Basal insulin analogues — glargine (U-100 and U-300), detemir, and degludec  provide sustained, peakless insulin coverage over 24 hours or beyond, reproducing physiological basal insulinaemia and reducing nocturnal hypoglycaemia relative to NPH insulin.

Insulin degludec (Tresiba), with its depot formation of multi-hexameric chains subcutaneously and duration of action exceeding 42 hours, achieves the most stable pharmacokinetic profile among basal insulins and demonstrates 40% lower confirmed hypoglycaemia rates compared to glargine U-100 in the SWITCH trials [43]. Ultra-rapid insulin analogues — faster-acting insulin aspart (Fiasp) with niacinamide addition and URLi (insulin lispro-aabc, Lyumjev) with treprostinil and citrate excipients — exhibit peak action at 40–45 minutes and 4-fold faster initial absorption than conventional rapid analogues, better replicating the first-phase insulin response to meals [44].

Fixed-ratio combination products co-formulating basal insulin with GLP-1RAs — iGlarLixi (insulin glargine/lixisenatide, Soliqua) and IDegLira (insulin degludec/liraglutide, Xultophy)  exploit complementary mechanisms to achieve HbA1c reductions of 1.3–1.9% in a single daily injection, while the GLP-1RA component mitigates insulin-induced weight gain and limits hypoglycaemia through glucose-dependent insulin secretion [45].

Emerging Pharmacological Targets

The pharmacological pipeline for diabetes management encompasses a diverse array of emerging targets reflecting systems-level understanding of T2DM pathophysiology. Dual GLP-1/GIP receptor agonists  tirzepatide (Mounjaro/Zepbound)  activate both GLP-1R and GIPR, the latter potentiating weight loss through central appetite suppression and adipocyte lipid metabolism, achieving unprecedented HbA1c reductions of 2.3% and weight loss of 21% in the SURPASS-5 trial [46]. The approval of tirzepatide across T2DM and obesity indications has created a new pharmacological category, with triple GLP-1/GIP/glucagon receptor agonists (retatrutide, CT-388) in Phase 3 development demonstrating even greater metabolic efficacy.

Finerenone  a non-steroidal, selective mineralocorticoid receptor antagonist  demonstrated 18% reduction in kidney failure and 13% reduction in cardiovascular events in the combined FIDELIO-DKD and FIGARO-DKD analysis (n=13,026 patients with T2DM and CKD), with a superior safety profile compared to steroidal MRAs (minimal hyperkalaemia, no gynaecomastia) [20]. Its approval for diabetic kidney disease represents a third organ-protective pharmacological pillar alongside RAAS blockade and SGLT2 inhibition in CKD management.

Additional emerging targets include: (1) Glucokinase activators (GKAs)  dorzagliatin received approval in China for T2DM, targeting the glucose-sensing glucokinase enzyme in both pancreatic beta-cells and hepatocytes; (2) Ileal bile acid transporter (IBAT) inhibitors — reducing enterohepatic bile acid recirculation and promoting GLP-1 secretion; (3) FGF21 analogues  efruxifermin and pegozafermin targeting the FGF21-FGFR1c-KLB axis for NASH and diabetes; and (4) Adipsin/C3aR pathway modulators targeting the complement-mediated pathway of adipose inflammation [47].

FIG.2 CURRENT TREATMENT OF DIABETES

FIG.3 PERSONALISED TREATMENT OF DIABETE

SPECIAL POPULATIONS IN DIABETES PHARMACOTHERAPY

Elderly Patients: Frailty, Polypharmacy, and De-intensification

Diabetes management in older adults (≥75 years) demands recalibration of the glycaemic target-treatment intensity equation to prioritise hypoglycaemia prevention, quality of life, and functional independence over tight HbA1c control [81]. Observational data from the ACCORD trial extension demonstrated a J-curve relationship between HbA1c and mortality in elderly T2DM patients, with both high (>9.0%) and low (<6.5%) HbA1c values associated with excess mortality — the latter driven by hypoglycaemia-related falls, cardiac arrhythmias, and impaired cognition. Current ADA guidelines recommend HbA1c targets of 7.5–8.0% for older adults with complex medical needs and 8.0–8.5% for those with very complex or poor health status.

Pharmacological de-intensification  reducing medication burden in elderly patients who have achieved targets below recommended levels or who develop frailty  is an underutilised intervention associated with improved patient wellbeing, reduced adverse effects, and lower healthcare costs. The DEPRESCRIBING framework (Determine goals; Evaluate eligibility; Pharmacological alternatives; Review risks; Engage patient; Simplify regimen; Communicate; Review; Institute safety monitoring; Broaden to non-pharmacological; Engage multidisciplinary; Gain consent) provides a structured approach applicable to geriatric diabetes management [82].

Diabetes in Pregnancy: Gestational and Pregestational

Pharmacological management of diabetes in pregnancy operates under strict constraints imposed by teratogenicity concerns, altered pharmacokinetics of pregnancy (increased renal clearance, expanded volume of distribution, changed protein binding), and fetal glucose-insulin dynamics [83]. Insulin remains the gold-standard pharmacotherapy across all trimesters  with human insulin analogues (aspart, lispro, detemir) demonstrating reassuring safety profiles in RCTs. Metformin, while not FDA-approved for GDM, is used as second-line therapy in many international guidelines and demonstrates non-inferiority to insulin for GDM glycaemic control (MiG trial) with important caveats: placental transfer exposes the fetus to metformin concentrations equal to maternal plasma, and long-term follow-up data suggest potential effects on offspring insulin resistance and adiposity.

SGLT2 inhibitors are contraindicated throughout pregnancy due to fetal renal tubular SGLT2 expression (particularly in the second and third trimesters) — glycosuria promotes fetal diuresis and potential oligohydramnios. GLP-1RAs lack adequate human pregnancy safety data and are not recommended. Thiazolidinediones are contraindicated. This pharmacological scarcity in pregnancy reinforces the paramount importance of lifestyle intervention  structured medical nutrition therapy achieving individualised carbohydrate targets, gestational weight gain within IOM guidelines, and post-prandial walking  as the primary therapeutic modality in GDM.

Type 1 Diabetes: Adjunct Therapy and Technology Integration

While insulin replacement therapy remains the cornerstone of T1DM management, adjunct non-insulin pharmacotherapy offers incremental glycaemic benefits in selected patients. SGLT2 inhibitors (empagliflozin, dapagliflozin the latter FDA-approved as T1DM adjunct until label revision) reduce HbA1c by 0.4–0.6% and body weight by 2–3 kg in T1DM, but carry a 3–6-fold increased risk of diabetic ketoacidosis (DKA) — necessitating patient education regarding sick-day rules, ketone monitoring, and insulin dose maintenance [84]. This risk was deemed sufficient for European Medicines Agency label revision restricting T1DM use for selected patients only, underscoring the critical importance of system-level safety pharmacovigilance.

Pramlintide  a synthetic amylin analogue  reduces post-prandial glucose excursions in T1DM by complementing insulin through gastric emptying delay, post-prandial glucagon suppression, and central appetite reduction. Hybrid closed-loop systems  integrating CGM, insulin pump, and control algorithms (MiniMed 780G, Control-IQ, Omnipod 5)  represent the frontier of T1DM management, achieving TIR of 70–80% compared to 50–65% with conventional insulin pump therapy, with breakthrough improvements in nocturnal hypoglycaemia and sleep quality [85].

PHARMACOVIGILANCE, SAFETY MONITORING, AND DRUG INTERACTIONS

The complex pharmacological landscape of diabetes management  characterised by multi-drug regimens spanning antidiabetic agents, cardiovascular medications, renally-active drugs, and emerging targeted therapies  mandates a systematic pharmacovigilance framework that extends beyond regulatory adverse event reporting to encompass proactive drug-drug interaction screening, population-level safety signal detection, and individual patient risk stratification [86].

Real-world pharmacovigilance data from national registries have yielded important safety signals complementing RCT-derived evidence. The disproportionality analysis from FAERS (FDA Adverse Event Reporting System) identified a 2.3-fold elevated reporting odds ratio for fournier's gangrene (necrotising fasciitis of the genitoperineum) with SGLT2i use — prompting FDA label updates in 2018 and clinical guidance for prompt evaluation of genital infections in SGLT2i-treated patients [87]. Similarly, GLP-1RA-associated pancreatitis signals from FAERS, while not substantiated in large CVOTs, necessitate clinical vigilance particularly in patients with prior pancreatitis, gallstones, or hypertriglyceridaemia.

Drug-drug interaction management in diabetic polypharmacy requires systematic screening. Clinically significant interactions include: (1) Fluoroquinolones (ciprofloxacin, levofloxacin) causing both hypoglycaemia and hyperglycaemia through dual KATP channel closure and pancreatic beta-cell toxicity; (2) Beta-blockers masking sympathoadrenergic hypoglycaemia warning symptoms (tachycardia, tremor) while preserving sweating, necessitating patient education particularly in insulin-treated patients; (3) Corticosteroids dramatically increasing insulin requirements by 30–100% through transient post-prandial hyperglycaemia requiring insulin regimen adjustment; (4) Thiazide diuretics at high doses impairing glucose tolerance through hypokalaemia-mediated insulin secretion impairment [65].

Renal function monitoring represents a critical safety parameter across the antidiabetic pharmacopeia. Metformin requires eGFR assessment at baseline and every 6–12 months, with dose halving at eGFR 30–45 and cessation below 30. SGLT2i require baseline eGFR (minimum eGFR 20 for empagliflozin/dapagliflozin per current labels) and hold during acute illness, radiographic contrast procedures, and major surgery to prevent acute kidney injury superimposed on volume depletion. DPP-4 inhibitors (except linagliptin) require dose reduction at eGFR <45 (sitagliptin), <50 (saxagliptin), or <30 (alogliptin). Sulfonylureas with active renal metabolites (glibenclamide, glimepiride) should be avoided in significant CKD.

FUTURE DIRECTIONS IN DIABETES SYSTEMS PHARMACOLOGY

Multi-Omics Integration and Precision Endocrinology

The convergence of genomics, transcriptomics, proteomics, metabolomics, and microbiomics  collectively termed multi-omics  with systems pharmacology modelling promises a transformative paradigm shift toward true precision endocrinology [88]. The T2D-GENES Consortium, Human Islet Research Network (HIRN), and Type 1 Diabetes TrialNet have generated multi-omics datasets enabling the construction of dynamic network models of beta-cell dysfunction that predict disease progression trajectories and pharmacological response profiles with unparalleled granularity. Metabolomic signatures  particularly branched-chain amino acid (BCAA) elevations, ceramide ratios, acylcarnitine profiles, and specific bile acid subspecies — have emerged as biomarkers of insulin resistance subtype, predicting differential GLP-1RA versus SGLT2i response with clinical utility approaching pharmacogenomic markers.

Proteomics-based cardiovascular risk stratification in T2DM leveraging high-throughput aptamer-based platforms (SomaScan, Olink) measuring thousands of circulating proteins  has identified novel biomarker panels (GDF-15, troponin T, NT-proBNP, IGFBP-2, and others) that improve cardiovascular risk prediction beyond traditional Framingham-based models by 15–25%, potentially enabling earlier initiation of cardioprotective pharmacotherapy in high-risk subgroups before ASCVD manifestation [89].

RNA Therapeutics and Gene-Based Interventions

The mRNA therapeutic revolution catalysed by COVID-19 vaccine development has opened transformative possibilities for diabetes pharmacology. mRNA encoding GLP-1, insulin, or glucokinase could theoretically enable sustained, regulated protein production following lipid nanoparticle delivery to hepatocytes  bypassing the injection burden of protein therapeutics while enabling precise tissue targeting and programmable expression duration [90]. Antisense oligonucleotides (ASOs) targeting ANGPTL3 (reducing triglycerides and LDL), PCSK9 (LDL reduction), and hepatic glucagon receptor (reducing fasting glucose) are in advanced clinical development as adjuncts to diabetes-associated dyslipidaemia and hyperglycaemia management.

CRISPR-Cas9 genome editing applications in T2DM research include correction of MODY-causing mutations in patient-derived iPSCs differentiated into insulin-producing beta-like cells  providing a potential autologous cell replacement therapy. TCF7L2 risk variant modification in beta-cells enhances insulin secretion in vitro, while PPARG gain-of-function editing could phenocopy TZD effects without systemic side effects [91]. While clinical translation of genomic editing in diabetes remains distant, these platforms will substantially accelerate the identification and validation of causal therapeutic targets identified through systems pharmacology network analyses.

Digital Therapeutics and Behavioural Pharmacology Integration

Digital therapeutics (DTx)  software-based medical interventions delivering evidence-based therapeutic interventions have achieved regulatory approval (FDA, CE mark) for T2DM management. Virta Health's continuous care model and Noom Med combine behavioural psychology, dietetic support, continuous CGM feedback, and telemedicine into integrated digital platforms demonstrating HbA1c reductions of 1.0–2.3% and medication reduction outcomes equivalent to intensive clinic-based interventions at substantially lower cost and greater accessibility [92]. BlueStar (Welldoc)  the first prescription digital therapeutic for T2DM  provides algorithm-driven coaching, medication reminders, and pattern recognition in CGM/SMBG data, achieving 1.9% HbA1c reduction in an FDA-reviewed pivotal study.

The pharmacology-behavioural psychology interface offers untapped synergistic potential. GLP-1RAs reduce not only appetite but food reward valuation through mesolimbic GLP-1R activation  a psychopharmacological mechanism that potentiates dietary adherence and may reduce addictive behaviour [93]. This neurobiological synergy between pharmacotherapy and behavioural intervention provides a mechanistic rationale for co-prescribing GLP-1RAs with structured behavioural weight management programs  an integration now codified in the 2023 ADA/EASD consensus statement. The pharmaceutical-behavioural ecosystem, integrating medication, digital feedback, and psychological support within a coherent systems model, represents the practical implementation of systems pharmacology in clinical diabetes care.

CONCLUSIONS

The management of diabetes mellitus  in its heterogeneous phenotypic manifestations and complex comorbidity contexts  demands a therapeutic paradigm that matches the biological complexity of the disease itself. Systems pharmacology, by integrating molecular target networks, multi-omics heterogeneity, clinical pharmacology, lifestyle biology, and digital health technologies into a coherent analytical framework, provides exactly this paradigm. The convergence of multiple mechanistic streams reviewed in this paper yields actionable conclusions.

First, the cardiorenal protective effects of GLP-1 receptor agonists and SGLT2 inhibitors  established through convergent cardiovascular outcome trial evidence and mechanistic network analysis  elevate these agents to the status of disease-modifying cardiovascular medicines, warranting their use as first-line or early-add-on therapy in any T2DM patient with CVD, heart failure, or CKD, independent of baseline HbA1c. Second, the molecular pharmacology of lifestyle interventions operating through AMPK, SIRT1, myokine signalling, gut microbiome reprogramming, and epigenetic modification  warrants their quantitative integration into treatment planning as pharmacologically equivalent to second-line oral antidiabetic agents. Third, pharmacogenomics and T2DM phenotypic clustering enable the prospective identification of pharmacological responder subgroups, transforming the historically empirical trial-and-error approach to drug selection into a mechanism-matched, evidence-anchored precision prescribing process.

The personalised treatment algorithm presented herein  stratified by cardiorenal comorbidity, metabolic phenotype, patient-level pharmacokinetic parameters, and lifestyle capability  operationalises these systems pharmacology insights into a clinically deployable framework applicable across primary and specialist care settings. As precision medicine technologies  polygenic risk scoring, CGM-derived phenotyping, AI-driven decision support, and multi-omics biomarker panels  achieve clinical feasibility, the framework presented here provides the conceptual scaffold into which these tools can be progressively integrated.

The transformation of diabetes care from a reactive, complication-driven model to a proactive, systems-informed, precision therapeutic paradigm is not merely a scientific aspiration but a clinical imperative  demanded by the scale of global diabetes burden, the preventable nature of its complications, and the rich mechanistic pharmacology available to those who approach it with sufficient intellectual breadth. Systems pharmacology offers that breadth.

REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels: International Diabetes Federation; 2021. Available from: https://www.diabetesatlas.org
2. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795.
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
4. Zhao S, Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PLoS One. 2010;5(7):e11764.
5. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–690.
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
7. Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–369.
8. Latent autoimmune diabetes in adults (LADA). Diabet Med. 2013;30(10):1155–1156.
9. Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467–477.
10. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603.
11. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA. 2007;104(6):1777–1782.
12. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852–871.
13. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157.
14. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.
15. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364–371.
16. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 2008;8(12):923–934.
17. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes and moderate renal impairment. N Engl J Med. 2021;384(2):129–139.
18. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625.
19. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
20. Pitt B, Filippatos G, Agarwal R, Anker SD, Bhatt DL, Januzzi JL, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263.
21. Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566–1576.
22. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642–1646.
23. Zhang CS, Li M, Ma T, Zong Y, Cui J, Feng JW, et al. Metformin activates AMPK through the lysosomal pathway. Cell Metab. 2016;24(4):521–522.
24. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type 2 diabetes and metformin-associated changes in gut microbiota. Nature. 2015;528(7581):262–266.
25. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865.
26. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21.
27. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
28. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
29. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
30. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187–215.
31. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al.; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690.
32. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002.
33. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22(1):104–112.
34. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495–502.
35. McMurray JJ, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
36. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
37. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
38. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632–644.
39. Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018;20(8):1988–1993.
40. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705.
41. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
42. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174–183.
43. Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175–184.
44. Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab. 2017;19(1):3–12.
45. Gough SC, Buse JB, Woo VC, Davies MJ, Rodbard HW, Linjawi S, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015;17(10):965–973.
46. Ludvik B, Giorgino F, Jódar E, Frias JP, Landó LF, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-5): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10300):583–598.
47. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
48. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al.; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34.
49. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–342.
50. Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, Campbell WW, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. Diabetes Ther. 2018;9(2):583–612.
51. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease. Nat Med. 2015;21(3):263–269.
52. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019;393(10170):434–445.
53. Lowe DA, Wu N, Rohdin-Bibby L, Moore AH, Kelly N, Liu YE, et al. Effects of time-restricted eating on weight loss and other metabolic parameters in women and men with overweight and obesity: The TREAT Randomized Clinical Trial. JAMA Intern Med. 2020;180(11):1491–1499.
54. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. 2013;17(2):162–184.
55. Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 2013;93(3):993–1017.
56. Sigal RJ, Kenny GP, Boulé NG, Wells GA, Prud'homme D, Fortier M, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147(6):357–369.
57. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457–465.
58. Wormgoor SG, Dalleck LC, Zinn C, Weatherall M, Rücklidge JJ, Drummond BK, et al. High-intensity interval training versus moderate-intensity continuous training on glycemic control and HbA1c: a systematic review and meta-analysis. Eur J Appl Physiol. 2021;121(7):1929–1940.
59. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069–1078.
60. van Son J, Nyklíček I, Pop VJ, Blonk MC, Erdtsieck RJ, Spooren PF, et al. The effects of a mindfulness-based intervention on emotional distress, quality of life, and HbA(1c) in outpatients with diabetes (DiaMind): a randomized controlled trial. Diabetes Care. 2013;36(4):823–830.
61. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141(11):846–850.
62. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56–68.
63. Guney E, Menche J, Vidal M, Barábasi AL. Network-based in silico drug efficacy screening. Nat Commun. 2016;7:10331.
64. Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–156.
65. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter genes on metformin pharmacokinetics and glycaemic control. Eur J Clin Pharmacol. 2010;66(2):141–148.
66. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77(1):1–16.
67. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504–2508.
68. Sathananthan A, Man CD, Micheletto F, Zinsmeister AR, Camilleri M, Giesler PD, et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care. 2010;33(9):2074–2076.
69. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59.
70. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–916.e7.
71. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–1640.
72. Hirsch IB, Brownlee M. Beyond hemoglobin A1c—need for additional markers of risk for diabetic microvascular complications. JAMA. 2010;303(22):2291–2292.
73. Ellahham S. Artificial intelligence application in diabetes care. Adv J Diabetol Metab. 2020;3(1):1017.
74. Russell SJ, Balliro C, Calhoun P, El-Khatib FH, Bhatt DL, Sherr JL, et al.; iLet Bionic Pancreas Research Group. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med. 2022;387(13):1161–1172.
75. Li K, Hernandez I, Goyal A, Gupta A, Kaltenbach LA, Bhatt DL, et al. Machine learning algorithms for predicting type 2 diabetes treatment response. J Clin Endocrinol Metab. 2022;107(2):e658–e669.
76. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786.
77. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines on the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–4140.
78. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al.; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–121.
79. Nathan DM; GRADE Study Research Group. Comparative Effectiveness of Glucose-Lowering Medications in Type 2 Diabetes. N Engl J Med. 2022;387(12):1083–1093.
80. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529.
81. American Diabetes Association Professional Practice Committee. Older Adults: Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S216–S229.
82. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–834.
83. Coustan DR, Lowe LP, Metzger BE, Dyer AR; HAPO Study Cooperative Research Group. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol. 2010;202(6):654.e1–6.
84. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258–2265.
85. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al.; iDCL Trial Research Group. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707–1717.
86. Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14(7–8):343–357.
87. Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764–769.
88. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148(6):1293–1307.
89. Ganz P, Heidecker B, Hveem K, Jonasson C, Kato S, Segal MR, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. 2016;315(23):2532–2541.
90. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–780.
91. Zhu H, Li Y. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. Exp Biol Med (Maywood). 2012;237(5):474–480.
92. Greenwood DA, Gee PM, Fatkin KJ, Peeples M. A systematic review of reviews evaluating technology-enabled diabetes self-management education and support. J Diabetes Sci Technol. 2017;11(5):1015–1027.
93. Blundell JE, Finlayson G. Is susceptibility to weight gain characterized by homeostatic or hedonic risk factors for overconsumption? Physiol Behav. 2004;82(1):21–25.